Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ManifestSeven Holdings Corporation (MNFSF)
Irvine, CA, US
ManifestSeven Holdings Corporation manages a comprehensive, multi-channel platform dedicated to the lawful cannabis industry. Its operations are structured across three distinct divisions: M7 Regulated, Inc., M7 Unregulated, Inc., and M7 Solutions, LLC. The company maintains industrial warehousing and retail storefront facilities that support cannabis distribution, delivery, and dispensary activities. Beyond this, it engages in the wholesale, distribution, and retail of supplementary products for licensed cannabis businesses and other related enterprises. ManifestSeven also offers financial solutions, serves as a capital hub, and delivers non-financial assistance for brand development and intellectual property ownership. Additionally, it provides commercial and regulatory-compliant services to authorized cannabis cultivators, manufacturers, distributors, and retailers. The corporate headquarters of ManifestSeven Holdings Corporation are situated in Irvine, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -90.00% | -100.00% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+63.9% ★ Q3'21: -11.9% (vs Q3'20)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-333.3% Q3'21: +94.8% (vs Q3'20)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-357.7% Q3'21: +1.1% (vs Q3'20)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-320.7% Q3'21: -21.1% (vs Q3'20)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-425.4% Q3'21: -29.4% (vs Q3'20)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-33.8% ★ Q3'21: +11.0% (vs Q3'20)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.43× Q3'21: -19.06× (vs Q3'20)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jordan Gerber | Chief Financial Officer | 146.5K | male |
| Sturges J. Karban | Chief Executive Officer & Director | 112.4K | male |
| Urban Smedeby | Director & Chief Strategy Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MNFSF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
